IngeniGen, a clinical microbial precision diagnosis company, receives tens of millions of yuan in Series A

IngeniGen, a clinical microbial precision diagnosis company, has raised tens of millions of yuan in a Series A financing round by Xiran Capital. Qingtong Capital served as exclusive financial advisor.

IngeniGen, a clinical microbial precision diagnosis company, has raised tens of millions of yuan in a Series A financing round by Xiran Capital. Qingtong Capital served as exclusive financial advisor.

IngeniGen said that proceeds from this round of financing will be used for the company’s research and development of new products, establishment of new technology platform and the optimization, upgrading and promotion of existing products.

Founded in 2014, IngeniGen focuses on the precise diagnosis and treatment of infectious diseases. The company develops clinical microbial sequencing and biological information analysis system designed to detect viruses and make diagnosis. The company’s product can perform DNA/RNA testing on clinical samples, enabling rapid diagnosis and treatment.

It is one of the earliest companies engaged in the research and development and application of pathogenic microorganism metagenome sequencing technology.

To date, IngeniGen has independently developed the IngeniSeq®️ clinical microbial metagenomic sequencing technology platform, and established a database and supporting bioinformatics analysis system covering 20,343 kinds of bacteria, fungi, viruses, parasites, etc., Sequencing microbial DNA and RNA and applying it to clinical precision treatment, guiding the rational use of anti-infective drugs, and improving prognosis and controlling nosocomial infections.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/04/ingenigen-a-clinical-microbial-precision-diagnosis-company-receives-tens-of-millions-of-yuan-in-series-a/.

Leave a Reply

Please Login to Comment